REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Clinical trials for REFRACTORY LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered cord blood cells take on tough lung cancers
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses specially engineered immune cells from umbilical cord blood, designed to better recognize and attack cancer cells…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs—atezolizumab (an immunotherapy that helps the immune system attack cancer) and cobimetinib (a targeted therapy that blocks cancer growth signals)—can shrink tumors or slow disease in people with advanced non-small cell lung cancer that…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Two-Drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New cocktail aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests whether adding two antibody drugs (necitumumab and trastuzumab) to the standard pill osimertinib can shrink tumors in people with advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone. About 30 adults with stage IV non-small cell lung…
Matched conditions: REFRACTORY LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC